Skip to Content
Merck

G7879

D-Glucose 6-phosphate sodium salt

≥98% (HPLC)

Synonym(s):

D(+)-Glucopyranose 6-phosphate sodium salt, G-6-P Na, Robison ester

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H12NaO9P
CAS Number:
54010-71-8
Molecular Weight:
282.12
UNSPSC Code:
12352201
NACRES:
NA.25
PubChem Substance ID:
24895324
EC Number:
258-921-0
Beilstein/REAXYS Number:
5787568
MDL number:
MFCD00006611

Product Name

D-Glucose 6-phosphate sodium salt, ≥98% (HPLC)

Quality Level

300

InChI

1S/C6H13O9P.Na/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8;/h2-10H,1H2,(H2,11,12,13);/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1

InChI key

ZALKNDISPIVVKC-WYRLRVFGSA-M

SMILES string

[Na+].O[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H](O)[C@H]1O

biological source

synthetic (organic)

assay

≥98% (HPLC)

form

crystalline

technique(s)

HPLC: suitable

color

white

useful pH range

4.0-5.0

mp

204 °C (dec.) (lit.)

solubility

water: 50 mg/mL, clear, colorless to very faintly yellow

cation traces

Na: 6.1-10.2% (anhydrous)

storage temp.

room temp

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

D-glucose-6-phosphate sodium can be used as an energy source for Mycobacterium tuberculosis.

Biochem/physiol Actions

In cells, D-glucose 6-phosphate (G6P) is generated when glucose is phosphorylated by hexokinase or glucokinase or by the conversion of glucose-1-phosphate by phosphoglucomutase during glycogenolysis. G6P lies at the beginning of both glycolysis and the pentose phosphate pathways. It also can be stored as glycogen when blood glucose levels are high.

Disclaimer

Non-hygroscopic, and very stable to atmospheric moisture at room temperature, unlike the disodium salt.

Other Notes

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000494323
0000494303
0000494323
0000494303
0000491601

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Iain J Abbott et al.
Antimicrobial agents and chemotherapy, 64(6) (2020-04-08)
There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against E. faecalis and E.
Iain J Abbott et al.
The Journal of antimicrobial chemotherapy, 75(4), 988-996 (2019-12-25)
To assess the antibacterial effects of a single 3 g oral fosfomycin dose on Escherichia coli and Klebsiella pneumoniae clinical isolates within a dynamic bladder infection model. An in vitro model simulating dynamic urinary fosfomycin concentrations was used. Target fosfomycin exposure
Iain J Abbott et al.
Antimicrobial agents and chemotherapy, 64(3) (2020-01-08)
Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple
Iain J Abbott et al.
Journal of microbiological methods, 171, 105861-105861 (2020-02-09)
The impact of the bladder environment on fosfomycin activity and treatment response is uncertain. Standard laboratory media does not reflect the biomatrix of urine, where limited nutritional factors are important for growth and antimicrobial kill rates. We compared fosfomycin activity
Calvin S Carter et al.
Cell metabolism, 32(4), 561-574 (2020-10-08)
Aberrant redox signaling underlies the pathophysiology of many chronic metabolic diseases, including type 2 diabetes (T2D). Methodologies aimed at rebalancing systemic redox homeostasis have had limited success. A noninvasive, sustained approach would enable the long-term control of redox signaling for
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service